Acesso livre
Acesso livre

Terapia Intensiva

[Preprint] Heparina para pacientes com Covid-19 moderada – “Em pacientes com Covid-19 moderada e D-dímero elevado, a terapia com heparina não reduziu significativamente o desfecho primário, mas reduziu as chances de morte em 28 dias de doença.”

12 Jul, 2021 | 11:41h

Heparin for Moderately Ill Patients with Covid-19 – medRxiv

Relacionado: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. E [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. E [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo randomizado | Outro estudo mostra que a azitromicina não melhora os desfechos em pacientes com Covid-19.

12 Jul, 2021 | 11:37h

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial – The Lancet Respiratory Medicine

Comentários: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases E Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine

Relacionado: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. E RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 E RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 E E Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 E Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19

 

Comentário no Twitter

 

Relatório oficial do American Thoracic Society Workshop | Entendendo o hospedeiro no tratamento da pneumonia.

12 Jul, 2021 | 11:26h

Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report – Annals of the American Thoracic Society

M-A | Comparação de eficácia e segurança de vancomicina, linezolida, tedizolida e daptomicina no tratamento de pacientes com infecção suspeita ou comprovada de pele e partes moles.

9 Jul, 2021 | 15:47h

Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven Complicated Skin and Soft Tissue Infections: An Updated Network Meta-Analysis – Infectious Diseases and Therapy

 

Comentário no Twitter

 

Avaliação e tratamento de doença cardiovascular em unidade de terapia intensiva.

9 Jul, 2021 | 15:45h

Assessment and management of cardiovascular disease in the intensive care unit – Heart

Série de casos | Plasmaférese em 3 pacientes com trombocitopenia trombótica imune induzida por vacina.

8 Jul, 2021 | 09:56h

Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia – New England Journal of Medicine

 

Comentário no Twitter

 

Revisão | Suporte ventilatório não invasivo e cateter nasal de alto fluxo como tratamentos de primeira linha na insuficiência respiratória hipoxêmica aguda e na síndrome da angústia respiratória aguda (SARA).

8 Jul, 2021 | 09:48h

Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS – Intensive Care Medicine

 

Comentário no Twitter

 

Preditores de morte e nova incapacidade após doença crítica: um estudo prospectivo de coorte multicêntrico.

8 Jul, 2021 | 09:47h

Predictors of death and new disability after critical illness: a multicentre prospective cohort study – Intensive Care Medicine

 

Comentário no Twitter

 

Diretriz da OMS sobre drogas para Covid-19 – Bloqueadores do receptor da interleucina-6 agora são recomendados para pacientes com Covid-19 grave ou crítica.

7 Jul, 2021 | 08:14h

A living WHO guideline on drugs for covid-19 – The BMJ

 

Comentário no Twitter

 

M-A | Associação entre administração de antagonistas de IL-6 e mortalidade entre pacientes hospitalizados com COVID-19 – “A redução absoluta de 4% no risco de mortalidade (de 25% para 21%) com inibidores de IL-6 somados a glicocorticoides pode não se refletir em pacientes com risco basal de mortalidade mais baixo, e parece não justificar o custo adicional e o risco de toxicidade para pacientes hospitalizados com pouca necessidade de oxigênio e curso clínico estável (do editorial).”

7 Jul, 2021 | 08:12h

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis – JAMA

Editorial: IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How? – JAMA

Comentários: Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients – King’s College London E WHO advises 2 monoclonal antibodies for severe COVID – CIDRAP

 

Comentário no Twitter (fio – clique para saber mais)

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.